Meeraus, Wilhelmine
Fry, Mark
Yeatman, Richard
Pimenta, Jeanne M.
Astrom, Jamila
Barth, Alan
McCorkindale, Sheila
Jones, Rupert
Leather, David
Funding for this research was provided by:
GlaxoSmithKline plc. (Study 207531; ClinicalTrials.gov ID NCT03152669)
Article History
Received: 20 April 2021
Accepted: 10 June 2021
First Online: 6 August 2021
Funding
: The extended Salford lung study was funded by GlaxoSmithKline plc. (study 207531; ClinicalTrials.gov ID NCT03152669). Funding for the journal’s Rapid Service and Open Access Fees was also provided by GlaxoSmithKline plc.
: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
: All authors contributed to the analysis and interpretation of the data; WM, MF and RJ were involved in the study concept and design; WM, AB, JA, RY, JMP and MF were involved in data acquisition.
: Editorial support (in the form of writing assistance, assembling tables and figures, collating author comments, grammatical editing, and referencing) was provided by Fraser Shearer, MSc, of Ashfield MedComms, an Ashfield Health company (Glasgow, UK) and was funded by GlaxoSmithKline plc.
: Ethical approval for this study was granted by the North West–Greater Manchester East Research Ethics Committee (REC Number 17/NW/0122).
: <b>Wilhelmine Meeraus:</b> Employment with and stock/share ownership in GlaxoSmithKline plc. <b>Alan Barth:</b> Employment with Graphnet Health Ltd, which has received funding from GlaxoSmithKline plc. <b>Jamila Astrom:</b> Employment with and stock/share ownership in GlaxoSmithKline plc. <b>Richard Yeatman:</b> Director of and major shareholder in IgniteData, which has received funding from GlaxoSmithKline plc. <b>Sheila McCorkindale:</b> Membership of the study governance board for the Salford Lung Study and has been an advisory board member for GlaxoSmithKline plc. <b>David Leather:</b> Employment with and stock/share ownership in GlaxoSmithKline plc. <b>Jeanne Pimenta:</b> Current employment with BioMarin Pharmaceutical Inc., employment with GlaxoSmithKline plc. at time of study and stock/share ownership in GlaxoSmithKline plc. <b>Mark Fry:</b> Employment with and stock/share ownership in GlaxoSmithKline plc. <b>Rupert Jones:</b> Current employment with Plymouth Marjon University. Grants from AstraZeneca, Teva Pharmaceutical Industries Ltd. and GlaxoSmithKline plc., and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline plc., Novartis, Nutricia and OPRI outside the submitted work.
: The datasets generated and/or analysed during the current study are not publicly available due to ongoing analyses preventing their wider release. Additionally, the secondary care data associated with this study will be under license from NHS Digital and cannot be released as such.